Peter Libby, MD, a cardiovascular medicine specialist at Brigham and Women’s Hospital, explains his research into COVID-19 and how it damages the endothelium of blood vessels. 

The randomized trial, expected to enroll at least 550 patients, will follow patients for a total of five years.

Simulation-based training can help cardiology fellows improve their TTE abilities, even when instructors or equipment are in short supply. 

What's next for TAVR? What trends should clinicians be focused on as time goes on? Kapadia shared his perspective in a new interview. 

A comparative meta-analysis found similar procedural outcomes, but higher 90-day mortality—partially attributable to a higher rate of comorbidities.

Read our monthly recap of some of the biggest FDA-related stories that have hit cardiology, including updates related to Cytokinetics, Dexcom and Abiomed. 

Researchers explored nearly 20 years of data from more than 18,000 patients, sharing their findings in the Journal of the American Heart Association.

Researchers recently found results yielded via subtraction CCTA to be similar to those produced by ICA in assessing stenosis grading.

After Moderna leadership revealed plans to potentially quadruple the price of its COVID-19 vaccine, Sen. Bernie Sanders (D-VT) and others criticized the move.

Less than a week after ringing the Nasdaq opening bell to showcase its long-awaited independence, GE HealthCare has announced a first strategic acquisition is in the works.